Egle Therapeutics, a Paris, France-based clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, raised €9.3M in state funding.
The funding was provided under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
The company intends to use the funds to expand operations and its R&D efforts.
Founded in 2020 as a spin-off from Institut Curie and led by CEO Christophe Quév, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with plans to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases. Its lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
During its Series A financing round in October 2021, the company raised €47M, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
FinSMEs
18/03/2025